Summary
To assess safety and tolerability at increasing dose levels of IO-202 in successive
cohorts of participants with AML with monocytic differentiation and CMML in order to
estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select
the recommended Phase 2 dose (RP2D)